Purple Biotech (PPBT) Depreciation and Depletion (2017 - 2026)
Purple Biotech (PPBT) posted quarterly Depreciation and Depletion of $65000.0 for Q1 2026, up 44.44% year-over-year from $45000.0 in Q1 2025, and up 22.64% quarter-over-quarter from $53000.0 in Q4 2025.
Purple Biotech (PPBT) Depreciation and Depletion (2017 - 2026) Analysis & Trends
Purple Biotech (PPBT) has reported Depreciation and Depletion for 10 consecutive years, with $65000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Depreciation and Depletion rose 44.44% year-over-year to $65000.0; the TTM figure through Mar 2026 stood at $223000.0 (up 21.86% YoY), while the FY2025 annual figure was $203000.0, up 9.14% from the prior year.
- Depreciation and Depletion grew to $65000.0 in Q1 2026 per PPBT's latest filing, from $53000.0 in the prior quarter.
- Across five years, Depreciation and Depletion topped out at $65000.0 in Q1 2026 and bottomed at $40000.0 in Q4 2024.
- Historically, Depreciation and Depletion has averaged $50117.6 across 5 years, with a median of $49000.0 in 2024.
- Annual changes were most pronounced in 2022 — Depreciation and Depletion sank 59.68% — and 2026, when it jumped 44.44%.
- Purple Biotech's Depreciation and Depletion stood at $50000.0 in 2022, then fell by 4.0% to $48000.0 in 2023, then fell by 16.67% to $40000.0 in 2024, then surged by 32.5% to $53000.0 in 2025, then increased by 22.64% to $65000.0 in 2026.
- Business Quant data shows PPBT's Depreciation and Depletion at $65000.0 in Q1 2026, $53000.0 in Q4 2025, and $58000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation and Depletion (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Purple Biotech | 130.35 | 130.35 | - | 70,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 65,000.00 |
| Mar 31, 2026 | 65,000.00 |
| Dec 31, 2025 | 53,000.00 |
| Dec 31, 2025 | 53,000.00 |
| Sep 30, 2025 | 58,000.00 |
| Sep 30, 2025 | 58,000.00 |
| Jun 30, 2025 | 47,000.00 |
| Jun 30, 2025 | 47,000.00 |
| Mar 31, 2025 | 45,000.00 |
| Mar 31, 2025 | 45,000.00 |
| Dec 31, 2024 | 40,000.00 |
| Dec 31, 2024 | 40,000.00 |
| Sep 30, 2024 | 49,000.00 |
| Sep 30, 2024 | 49,000.00 |
| Jun 30, 2024 | 49,000.00 |
| Jun 30, 2024 | 49,000.00 |
| Mar 31, 2024 | 48,000.00 |
| Mar 31, 2024 | 48,000.00 |
| Dec 31, 2023 | 48,000.00 |
| Dec 31, 2023 | 48,000.00 |